Overview

Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

Status:
Terminated

Trial end date:
2021-02-22

Target enrollment:

Participant gender:

Summary

To assess the safety and tolerability of long-term pimavanserin treatment in subjects with major depressive disorder and inadequate response to antidepressant treatment.

Phase:

Phase 3

Details

Lead Sponsor:

ACADIA Pharmaceuticals Inc.

Treatments:

Antidepressive Agents
Pimavanserin